


# GSK Q3 2019 results

GSK delivers sales growth across all three businesses

All % at constant exchange rates (CER)



Total Group operating margin  
**22.9%**

Adjusted Group operating margin  
**29.7%**

Total EPS  
**31.4p**  
-1%

Adjusted EPS  
**38.6p**  
+1%

Year to date free cash flow  
**£2.5bn**

Dividend  
**19p**

See **press release** on [www.gsk.com](http://www.gsk.com) for full details on Q3 2019.

Please read the cautionary statement regarding the definitions and reconciliations for non-IFRS measures and the **forward-looking statements** on pages 9 and 59 of the press release.

CER% represents growth at constant exchange rates. For a full explanation please see page 58 of the press release.

\*Pro-forma growth +3%

\*\*Pro-forma growth +6%

**Cancer tumour on ovarian wall**

